273 related articles for article (PubMed ID: 28919986)
1. Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.
Jacquelot N; Pitt JM; Enot DP; Roberti MP; Duong CPM; Rusakiewicz S; Eggermont AM; Zitvogel L
Oncoimmunology; 2017; 6(8):e1299303. PubMed ID: 28919986
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma.
Aris M; Mordoh J; Barrio MM
Front Immunol; 2017; 8():1024. PubMed ID: 28970830
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers in melanoma.
Griewank KG
Scand J Clin Lab Invest Suppl; 2016; 245():S104-12. PubMed ID: 27467728
[TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
[TBL] [Abstract][Full Text] [Related]
8. Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.
Garg AD; Vandenberk L; Van Woensel M; Belmans J; Schaaf M; Boon L; De Vleeschouwer S; Agostinis P
Oncoimmunology; 2017; 6(4):e1295903. PubMed ID: 28507806
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma.
Puglisi R; Bellenghi M; Pontecorvi G; Pallante G; Carè A; Mattia G
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207514
[TBL] [Abstract][Full Text] [Related]
10. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
12. Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy.
Strudel M; Festino L; Vanella V; Beretta M; Marincola FM; Ascierto PA
Curr Med Chem; 2020; 27(17):2792-2813. PubMed ID: 31804158
[TBL] [Abstract][Full Text] [Related]
13. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
14. Predictors of responses to immune checkpoint blockade in advanced melanoma.
Jacquelot N; Roberti MP; Enot DP; Rusakiewicz S; Ternès N; Jegou S; Woods DM; Sodré AL; Hansen M; Meirow Y; Sade-Feldman M; Burra A; Kwek SS; Flament C; Messaoudene M; Duong CPM; Chen L; Kwon BS; Anderson AC; Kuchroo VK; Weide B; Aubin F; Borg C; Dalle S; Beatrix O; Ayyoub M; Balme B; Tomasic G; Di Giacomo AM; Maio M; Schadendorf D; Melero I; Dréno B; Khammari A; Dummer R; Levesque M; Koguchi Y; Fong L; Lotem M; Baniyash M; Schmidt H; Svane IM; Kroemer G; Marabelle A; Michiels S; Cavalcanti A; Smyth MJ; Weber JS; Eggermont AM; Zitvogel L
Nat Commun; 2017 Sep; 8(1):592. PubMed ID: 28928380
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
[TBL] [Abstract][Full Text] [Related]
17. Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives.
Marra A; Ferrone CR; Fusciello C; Scognamiglio G; Ferrone S; Pepe S; Perri F; Sabbatino F
Anticancer Agents Med Chem; 2018; 18(2):166-181. PubMed ID: 29256359
[TBL] [Abstract][Full Text] [Related]
18. Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy.
Hou Q; Xu H
Adv Exp Med Biol; 2020; 1248():143-166. PubMed ID: 32185710
[TBL] [Abstract][Full Text] [Related]
19. CD103
Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
[No Abstract] [Full Text] [Related]
20. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.
Lee N; Zakka LR; Mihm MC; Schatton T
Pathology; 2016 Feb; 48(2):177-87. PubMed ID: 27020390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
